The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1364
In Brief: A Booster Dose of Meningococcal Vaccine for Adolescents
Download PDF:   US English
Med Lett Drugs Ther. 2011 May 16;53(1364):37
Disclosures
Objective(s)
 Select a term to see related articles  Menactra   Meningococcal vaccine   Menveo   Neisseria meningitidis   Pediatrics   vaccines 

Evidence of waning immunity by 5 years post-vaccination has led the US Advisory Committee on Immunization Practices (ACIP) to recommend, in addition to a primary dose of meningococcal conjugate vaccine at 11 or 12 years of age, a booster dose at age 16. Adolescents who receive a first dose of the vaccine at age 13-15 should receive a booster dose at 16-18 (before college). Those who receive their first dose at ≥16 years of age do not need a booster dose. Routine vaccination of healthy persons who are not at increased risk for exposure to Neisseria meningitidis is not recommended after age 21.1

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article